Niagen Bioscience, Inc. NAGE
Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries.
On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M | $59.3M | $46.3M | $31.6M | $21.2M | $21.7M |
| Cost of revenue | $46.2M | $38.0M | $32.8M | $29.3M | $26.0M | $24.0M | $20.5M | $15.5M | $10.7M | $11.3M |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M | $35.3M | $25.8M | $16.1M | $10.5M | $10.4M |
| R&D | $6.3M | $6.0M | $5.0M | $4.8M | $3.8M | $3.4M | $4.4M | $5.5M | $4.0M | $2.5M |
| SG&A | $27.1M | $18.4M | $25.0M | $28.3M | $36.4M | $30.8M | $34.3M | $27.1M | $17.6M | $9.2M |
| Total operating expenses | $66.9M | $53.9M | $56.4M | $61.4M | $68.6M | $55.1M | $57.1M | $49.2M | $26.9M | $13.3M |
| Operating income | $16.3M | $7.7M | -$5.6M | -$18.6M | -$27.1M | -$19.9M | -$31.3M | -$33.2M | -$16.4M | -$2.9M |
| Interest expense | — | — | $661.0K | $3.0K | $55.0K | $71.0K | $847.0K | $79.0K | $153.0K | $333.3K |
| Pre-tax income | $18.2M | $8.9M | -$4.9M | — | — | — | — | — | -$16.5M | -$3.6M |
| Income tax | $810.0K | $305.0K | $0 | — | — | — | — | — | $0 | $0 |
| Net income | $17.4M | $8.6M | -$4.9M | -$16.5M | -$27.1M | -$19.9M | -$32.1M | -$33.3M | -$11.4M | -$2.9M |
| EPS, basic | 0.22 | 0.11 | -0.07 | -0.24 | -0.40 | -0.33 | — | — | — | — |
| EPS, diluted | 0.20 | 0.11 | -0.07 | -0.24 | -0.40 | -0.33 | -0.56 | -0.61 | -0.26 | -0.08 |
| Shares, diluted (wtd. avg.) | $85.4M | $78.1M | $75.0M | $69.7M | $67.2M | $61.1M | — | — | — | $37.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $64.8M | $44.7M | $27.3M | $20.4M | $28.2M | $16.7M | $18.8M | $22.6M | — | — |
| Receivables | $9.7M | $7.8M | — | $8.5M | $5.2M | $2.7M | $2.2M | $4.4M | $5.3M | $5.9M |
| Inventory | — | $9.2M | $14.5M | $14.7M | $13.6M | $11.7M | $11.5M | $8.2M | $5.8M | $7.9M |
| Total current assets | $96.8M | $64.1M | $49.5M | $46.6M | $48.9M | $32.2M | $33.5M | $36.5M | $57.2M | $15.7M |
| Property, plant and equipment | — | — | — | — | — | $3.2M | $3.8M | $3.6M | $2.9M | $1.8M |
| Other intangibles | $5.7M | $359.0K | $510.0K | $671.0K | $857.0K | $1.1M | $1.3M | $1.5M | $1.7M | $486.2K |
| Total assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M | $38.4M | $40.2M | $42.2M | $62.7M | $19.8M |
| Accounts payable | $10.8M | $8.5M | $10.2M | $9.7M | $10.4M | $9.4M | $9.6M | $9.5M | $3.7M | $6.0M |
| Short-term debt | — | — | — | — | — | — | — | — | — | $0 |
| Total current liabilities | $19.9M | $17.9M | $20.6M | $17.9M | $17.6M | $16.5M | $15.1M | $14.4M | $8.1M | $8.9M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $0 |
| Total liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M | $21.9M | $19.8M | $15.1M | $8.9M | $9.8M |
| Retained earnings | -$164.5M | -$181.9M | -$190.5M | -$185.5M | -$169.0M | -$141.8M | -$121.9M | -$89.8M | -$56.6M | -$45.2M |
| Total equity | $76.5M | $46.1M | $28.5M | $28.7M | $31.7M | $16.4M | $20.4M | $27.2M | $53.8M | $10.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.5M | $12.1M | $7.1M | -$15.1M | -$24.2M | -$10.6M | -$20.4M | -$20.9M | -$9.8M | -$2.9M |
| Depreciation and amortisation | $612.0K | $663.0K | $870.0K | $869.0K | $890.0K | $871.0K | $762.0K | $607.0K | $510.0K | $332.0K |
| Stock-based compensation | $6.1M | $3.7M | $4.8M | $5.7M | $6.2M | $6.9M | $7.2M | $6.4M | $4.6M | $1.2M |
| Capital expenditure | — | — | — | — | — | — | $743.0K | $1.3M | $1.2M | $1.5M |
| Investing cash flow | -$292.0K | -$143.0K | -$143.0K | -$334.0K | -$409.0K | -$165.0K | -$249.0K | -$1.8M | $4.6M | -$1.7M |
| Financing cash flow | $6.9M | $5.4M | -$90.0K | $7.7M | $36.1M | $8.7M | $16.9M | -$90.0K | $48.9M | $754.3K |
| Buybacks | $251.0K | $0 | — | — | — | — | — | $404.0K | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001386570-26-000022.
Others in SIC 2833
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $5.12B | — | — |
| TRLV | Trulieve Cannabis Corp. | $2.33B | — | -0.4% |
| CRON | Cronos Group Inc. | $1.20B | — | 24.6% |
| TLRY | Tilray Brands, Inc. | $612.9M | — | 11.5% |
| CGC | Canopy Growth Corp | $411.5M | — | — |
| USNA | USANA HEALTH SCIENCES INC | $276.4M | 25.8x | 8.3% |
| FTLF | FITLIFE BRANDS, INC. | $92.2M | 15.6x | 26.4% |
| BTMD | biote Corp. | $44.2M | 2.1x | -2.5% |